Lantheus Holdings, Inc. (LNTH) Fair Value 2026

LNTH · Drug Manufacturers - Specialty & Generic ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

9.3 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (18/100)

Quick Summary — As of 2026-08-27, Lantheus Holdings, Inc. (LNTH) trades at $100.47, versus a $126.61 median fair value across its 10 active models — 26.0% above the current price. QOC: 9.3/10. Value Trap Risk: 18/100 (SAFE). 10/13 models active. Within that set, the Bayesian DCF component alone returns $189.90.

Key Facts

Ticker
LNTH
Price
$100.47
Quality Score
9.3/10
Value Trap Risk
18/100
Models Active
10/13
Last Updated
Strength: Bayesian DCF suggests +89.0% upside with 67% confidence
Risk: Limited model coverage (10/13) may reduce confidence

Is Lantheus Holdings, Inc. (LNTH) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Lantheus Holdings, Inc. (LNTH) appears undervalued as of : the median of 10 independent fair value estimates is $126.61, 26.0% above the current price of $100.47. Estimates range from $49.02 to $225.77. LNTH scores 9.3/10 on fundamental quality and 18/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. LNTH’s +26.0% gap is wider than that market norm, and the Drug Manufacturers - Specialty & Generic sector median is -1.4%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Lantheus Holdings, Inc. Stock in 2026? →

What Fair Value Does Each Model Give LNTH?

10 Intrinsic Value Models vs. Current Price ($100.47)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $189.90 +89.0%
Ensemble · Low Conviction
 $127.18 +26.6%
Scenario · High Conviction
 $131.92 +31.3%
Intrinsic · High Conviction
 $49.02 -51.2%
Unlock the Full Matrix

Access 6 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is LNTH's Fair Value Range?

Spread across 10 independent models · $49.02 to $225.77

CirclFi's 10 active models place Lantheus Holdings, Inc. (LNTH) between $49.02 and $225.77 per share, a spread of 140% of the median. The median of that range — $126.61 — is the fair value CirclFi publishes for LNTH, against a current price of $100.47.

Low · EROICHigh · Markov DDM
$49.02median $126.61$225.77
Where the range comes from
Most bearish modelEROIC Spread$49.02
Most bullish modelMarkov DDM$225.77
Model agreement6 bullish · 4 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for LNTH. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on LNTH, not a CirclFi price target. How each model works →

What Is Lantheus Holdings, Inc. (LNTH) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Lantheus Holdings, Inc.'s intrinsic value is estimated at a median fair value of $126.61. While the stock appears modestly undervalued at $100.47 (implied upside of +26.0%), our analysis suggests a thinner margin of safety across 6 of 10 bullish models. Notably, Markov DDM sees the most upside at +124.7% (fair value: $225.77), while EROIC is the most conservative at -51.2% ($49.02). The spread between these extremes — +175.9% — reveals how different analytical frameworks can reach starkly different conclusions.

What Do the Models Say About LNTH?

10 of 13 models are currently active for LNTH. Of these, 6 models suggest upside while 4 models suggest overvaluation. Taken together, their median fair value for LNTH is $126.61 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $189.90 on its own, implying +89.0% upside from the current price. See which stocks rank higher →

How Does LNTH Rank in Drug Manufacturers - Specialty & Generic?

Among 110 Drug Manufacturers - Specialty & Generic stocks, LNTH ranks #4 by Quality of Company score. CirclFi's QOC score of 9.3/10 evaluates 32 fundamental signals. A score of 9.3 places LNTH in the top tier.

See all Most Undervalued Drug Manufacturers - Specialty & Generic Stocks →

The Drug Manufacturers - Specialty & Generic sector introduces analytical considerations specific to healthcare company businesses. For Lantheus Holdings, Inc., metrics like R&D productivity ratio provide important context that general-purpose valuation models may underweight.

Is LNTH a Value Trap?

CirclFi's Value Trap algorithm assigns LNTH a score of 18/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Lantheus Holdings, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Lantheus Holdings, Inc. scores 9.3 out of 10 on our 32-signal quality assessment, a elite rating that ranks among the highest-quality businesses in our coverage universe. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +175.9% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every LNTH valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across LNTH's 10 active models, average confidence is 46%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Lantheus Holdings, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Drug Manufacturers - Specialty & Generic Stocks Should You Also Analyze?

9 related Drug Manufacturers - Specialty & Generic stocks with 13-model coverage

ZTSZoetis Inc.QOC 9.3NBIXNeurocrine Biosciences, Inc.QOC 9.1AMPHAmphastar Pharmaceuticals, Inc.QOC 9.4ANIPANI Pharmaceuticals, Inc.QOC 9.0UTHRUnited Therapeutics CorporationQOC 9.6ELTPElite Pharmaceuticals, Inc.QOC 8.8LQDALiquidia CorporationQOC 7.0AQSTAquestive Therapeutics, Inc.QOC 6.0PRFXPRF Technologies Ltd.QOC 4.7

Read investment analysis: ZTS · NBIX · AMPH · ANIP · UTHR · ELTP · LQDA · AQST · PRFX

Which Other Stocks Have a Similar Quality Score to LNTH?

7 companies across all industries closest to LNTH’s Quality of Company score of 9.3/10.

ALLEAllegion plcQOC 9.3NTAPNetApp, Inc.QOC 9.3FSLRFirst Solar, Inc.QOC 9.3MSAMSA Safety IncorporatedQOC 9.3ALRMAlarm.com Holdings, Inc.QOC 9.3GWWW.W. Grainger, Inc.QOC 9.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: ALLE · NTAP · FSLR · MSA · ALRM · GWW · NVDA

Where Does LNTH Sit in CirclFi's Drug Manufacturers - Specialty & Generic Rankings?

LNTH is ranked against every other Drug Manufacturers - Specialty & Generic stock CirclFi covers in each of these screens.

See all Drug Manufacturers - Specialty & Generic stocks ranked →

What Else Do Investors Ask About Lantheus Holdings, Inc.’s Valuation?

What is Lantheus Holdings, Inc.'s intrinsic value in 2026?

CirclFi puts Lantheus Holdings, Inc. (LNTH)'s intrinsic value at $126.61 — the median of 10 independent model estimates as of 2026-08-27, ranging from $49.02 to $225.77. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $189.90 on its own. The Quality of Company score is 9.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is LNTH overvalued or undervalued right now?

At $100.47, 6 of 10 active models suggest LNTH may be undervalued, while 4 indicate potential overvaluation. The median of all 10 fair value estimates is $126.61, 26.0% above the current price of $100.47 — a consensus view that LNTH is undervalued. The assessment depends on which methodology best fits Lantheus Holdings, Inc.'s business model in Drug Manufacturers - Specialty & Generic.

What does a Quality of Company score of 9.3 mean for LNTH?

Lantheus Holdings, Inc.'s QOC of 9.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on LNTH?

CirclFi analyzes LNTH with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on LNTH?

Of the 10 models currently active on LNTH, Markov DDM is the most bullish at $225.77 per share, and EROIC Spread is the most bearish at $49.02. CirclFi's published fair value for LNTH is the median of that range, $126.61, not either extreme. The gap between the two ends equals 140% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is LNTH a value trap in 2026?

Lantheus Holdings, Inc.'s Value Trap score is 18/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Lantheus Holdings, Inc. (LNTH) has a median fair value of $126.61 — 26.0% above the current price of $100.47 — as of 2026-08-27.” Source: circlfi.com/stock/LNTH/ · Methodology
Primary sources for this LNTH valuation
  • Financial statements: Lantheus Holdings, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001521036) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for LNTH as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on LNTH.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for LNTH Unlock All 10 — $39/mo